Preclinical News and Research

RSS

Moirai Orthopaedics receives FDA approval for IDE application to initiate clinical study of PIR System

Moirai Orthopaedics, L.L.C., an orthopaedic implant development company based in Metairie, Louisiana, is pleased to announce it has received approval from the US Food and Drug Administration for its Investigational Device Exemption (IDE) application to initiate clinical study of the company's Pyrocarbon Implant Replacement (PIR) System.

16 Apr 2015

Pivotal enters into sales, distribution agreement for BeneFishial family of products

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has entered into a Memorandum of Understanding with Korea Animal Medical Science Institute and its newly created affiliate for the exclusive sales and distribution of the BeneFishial family of products.

15 Apr 2015

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Cardio3 BioSciences (C3BS), a leader in engineered cell-therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced the enrollment of the first patient in a Phase I clinical trial evaluating the Company’s lead CAR T-Cell therapy, NKG2D CAR T-Cell, in blood cancer patients with acute myeloid leukemia (AML) or multiple myeloma (MM).

15 Apr 2015

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

Small cell lung cancer (SCLC) will be the concentrated focus when 100 global experts in the field meet for a workshop hosted by the International Association for the Study of Lung Cancer on April 22-24, 2015 at Memorial Sloan Kettering Cancer Center in New York City.

15 Apr 2015

MR Solutions offers range of MRI scanners that can be placed within Class 3 and 4 laboratories

For the first time a 3T, 4.7T or 7T preclinical bench top MRI scanner can be placed inside a Class 3 or 4 laboratory providing superior soft tissue contrast and high spatial resolution. This is because the revolutionary new high powered MRI scanners from MR Solutions, which are cryogen free, no longer need any external venting.

From MR Solutions 15 Apr 2015

Humabs BioMed reports clinical milestone in medImmune partnership

Humabs BioMed SA, a leading Swiss antibody therapeutics company, today announced that a novel antibody developed through its proprietary Cellclone technology will be investigated for the treatment of influenza A...

14 Apr 2015

Administration of selenide protects heart tissue post cardiac arrest, shows study

Damage to heart muscle from insufficient blood supply during cardiac arrest and reperfusion injury after blood flow is restored can be reduced by nearly 90 percent if selenide, a form of the essential nutrient selenium, is administered intravenously in the wake of the attack, according to a new preclinical study by researchers at Fred Hutchinson Cancer Research Center.

10 Apr 2015

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 (“miR-103/107”) for the treatment of Non Alcoholic Steatohepatitis (“NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies’ strategic alliance to discover, develop and commercialize microRNA therapeutics.

9 Apr 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26.

8 Apr 2015

National MS Society commits $28 million to support new MS research projects, training awards

The National Multiple Sclerosis Society has committed $28 million to support an expected 84 new MS research projects and training awards. These are part of a comprehensive research strategy aimed at stopping MS, restoring function that has been lost, and ending the disease forever – for every single person with MS.

8 Apr 2015

Nabriva Therapeutics completes $120 million Series B financing

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, today announced the successful completion of a $120 million Series B financing.

7 Apr 2015

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health.

6 Apr 2015

New biodegradable membrane reduces wound healing time by 50%

Treatments to regenerate skin from burns become tedious and long lasting; however, Mexican researchers developed a biodegradable membrane that allows to transfer skin cells (keratinocytes) to burn wounds, when placed on the wound. The method reduces healing time by 50 percent.

3 Apr 2015

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

Delving into the world of the extremely small, researchers are exploring how biodegradable nanoparticles can precisely deliver anticancer drugs to attack neuroblastoma, an often-deadly children's cancer.

3 Apr 2015

ImmunoClin receives controlled drug license to supply, produce schedule 1 drugs in UK

ImmunoClin Corporation, a healthcare company specialized in personalized medicine, announces that its wholly owned subsidiary, ImmunoClin Ltd., received a controlled drug license from the UK government to possess, supply and produce schedule 1 drugs in its UK laboratory.

2 Apr 2015

Study: APOSEC protein concentrate reduces severity of damage after spinal cord injuries

In tests conducted on animals, the APOSEC protein concentrate extracted from white blood cells has reduced the severity of damage after an accident involving spinal cord injuries when the agent was injected in the abdominal cavity 40 minutes after the acute lesion. As a result, severe consequential paralyses can be prevented.

2 Apr 2015

Selvita commences IND-enabling studies for its first oncology drug candidate

Selvita, the largest drug discovery company in Central and Eastern Europe, announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate.

1 Apr 2015

NIH awards $2.1 million grant to counter antibiotic resistance in Gram-negative bacteria

The National Institutes of Health has awarded Dr. Walter Fast, associate professor of medicinal chemistry at The University of Texas at Austin's College of Pharmacy, a four-year $2.1 million grant to develop small-molecules that counter antibiotic resistance in Gram-negative bacteria. If successful, the research could lead to new drugs for treating bacterial infections that are resistant to most antibiotics.

1 Apr 2015

Aeterna Zentaris inks Material Transfer Agreement with MUSC

Aeterna Zentaris Inc. today announced that it has agreed to transfer its discovery library of roughly 100,000 unique compounds to the South Carolina Center for Therapeutic Discovery & Development (the Center) pursuant to a just concluded Material Transfer Agreement.

31 Mar 2015

Biomedical researchers successfully convert microbubble technology into nanoparticles

Biomedical researchers led by Dr. Gang Zheng at Princess Margaret Cancer Centre have successfully converted microbubble technology already used in diagnostic imaging into nanoparticles that stay trapped in tumours to potentially deliver targeted, therapeutic payloads.

31 Mar 2015

Preclinical News and Research

Moirai Orthopaedics receives FDA approval for IDE application to initiate clinical study of PIR System

Pivotal enters into sales, distribution agreement for BeneFishial family of products

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

MR Solutions offers range of MRI scanners that can be placed within Class 3 and 4 laboratories

Humabs BioMed reports clinical milestone in medImmune partnership

Administration of selenide protects heart tissue post cardiac arrest, shows study

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

National MS Society commits $28 million to support new MS research projects, training awards

Nabriva Therapeutics completes $120 million Series B financing

MabVax closes $11.6 million in private placement

New biodegradable membrane reduces wound healing time by 50%

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

ImmunoClin receives controlled drug license to supply, produce schedule 1 drugs in UK

Study: APOSEC protein concentrate reduces severity of damage after spinal cord injuries

Selvita commences IND-enabling studies for its first oncology drug candidate

NIH awards $2.1 million grant to counter antibiotic resistance in Gram-negative bacteria

Aeterna Zentaris inks Material Transfer Agreement with MUSC

Biomedical researchers successfully convert microbubble technology into nanoparticles

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics